GlassScriptPhysician profile
Anand K Bhat
NPI 1992084750
$9,222.11
in general payments reported to CMS, 2019-2025
31 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 77% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $87.70 · 2021: $1,452 · 2022: $1,242 · 2023: $2,013 · 2024: $1,675 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,163 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.62 |
| Education | $119.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,594.79 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,501.11 | 2021-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $1,094.54 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $993.08 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Itamar Medical INC | $385.95 | 2023-2025 | Watchpatone |
| Genzyme Corporation | $377.78 | 2021-2025 | |
| Genentech USA, INC. | $320.27 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $235.53 | 2020-2024 | Cuvitru, Gattex |
| Ars Pharmaceuticals Operations, INC. | $159.70 | 2025 | Neffy |
| Pharming Healthcare, INC. | $151.29 | 2022-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $144.43 | 2019-2025 | |
| Horizon Therapeutics Plc | $136.29 | 2021-2023 | Actimmune |
| Jazz Pharmaceuticals INC. | $127.36 | 2019 | |
| Mylan Specialty L.P. | $125.00 | 2023 | Yupelri |
| Ionis Pharmaceuticals, INC. | $125.00 | 2025 | Dawnzera |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $119.23 | 2021-2023 | Hizentra |
| Alk-Abello, INC | $96.65 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $72.24 | 2022 | |
| Kaleo, INC. | $71.82 | 2022-2023 | Auvi-Q |
| Harmony Biosciences LLC | $65.90 | 2025 | |
| Jubilant Hollisterstier LLC | $56.05 | 2023-2024 | |
| Octapharma USA, INC. | $42.57 | 2021 | |
| Blueprint Medicines Corporation | $37.55 | 2021-2023 | Ayvakit |
| Inspire Medical Systems, INC. | $36.96 | 2025 | Inspire |
| Phadia US INC. | $36.55 | 2023-2024 | Immunocap |
| Hospira, INC. | $30.18 | 2024-2025 | |
| Incyte Corporation | $19.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.26 | 2022 | |
| Greer Laboratories, INC. | $17.75 | 2023 | Oralair |
| E.R. Squibb & Sons, L.L.C. | $16.41 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.